Comparing Traditional vs. Enhanced Operations

Scenario: Pharmaceutical Product Recall and Traceability

Traditional EDI + Manual Investigation:

1. Contamination suspected in pharmaceutical batch
2. EDI records show shipment transactions (850 PO, 856 ASN, 810 invoice)
3. Must manually contact all distributors via phone/email
4. Each distributor checks their EDI logs and database records
5. Compile information from multiple disconnected systems
6. Track which specific units went to which locations
7. Investigation time: 5-7 days minimum
8. Cost: Hundreds of staff hours across multiple organizations
9. Risk: Contaminated products remain in circulation during investigation
10. Financial impact: Extended recall period affects more locations, higher liability

EDI + Blockchain Enhanced System:

1. Contamination suspected in pharmaceutical batch
2. Query blockchain using batch number or serial number
3. Blockchain instantly shows:

   • Every location that received units from this batch
   • Exact timestamps of all transfers
   • Current custody holders
   • Complete chain of custody with digital signatures
4. EDI continues handling routine transaction documents
5. Investigation time: Minutes to hours
6. Cost: Minimal—automated query replaces manual investigation
7. Risk mitigation: Rapid containment limits exposure
8. Financial impact: Targeted recall reduces scope and cost by 60-70%

The Enhancement: EDI handled the transactional workflow—purchase orders, shipments, invoices. Blockchain added verifiable traceability that turned a multi-day crisis management exercise into a rapid, precise response. The FDA pilot proved this concept: blockchain maintained data privacy through permissioned access while enabling the speed and accuracy required for patient safety.

Real-World Context: The U.S. Drug Supply Chain Security Act requires this level of traceability by 2023. Companies using only EDI struggle to meet these requirements; blockchain enhancement makes compliance achievable while preserving existing EDI investments.